# Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI

> **NCT02593539** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 5 (actual)

## Conditions studied

- Activated PI3K-delta Syndrome

## Interventions

- **DRUG:** Nemiralisib

## Key facts

- **NCT ID:** NCT02593539
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-22
- **Primary completion:** 2020-06-04
- **Final completion:** 2020-06-04
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2021-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02593539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02593539, "Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT02593539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*